Sources of bias in specimens for research about molecular markers for cancer.
暂无分享,去创建一个
[1] Sudhir Srivastava,et al. Toward a Robust System for Biomarker Triage and Validation – EDRN Experience , 2009 .
[2] William E Grizzle,et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. , 2009, Journal of proteome research.
[3] P. Laird,et al. Ovarian Cancer Early Detection Claims Are Biased , 2008, Clinical Cancer Research.
[4] D. Ward,et al. Diagnostic markers for early detection of ovarian cancer (Clinical Cancer Research (2008) 14, (1065-1072)) , 2008 .
[5] David F Ransohoff,et al. The process to discover and develop biomarkers for cancer: a work in progress. , 2008, Journal of the National Cancer Institute.
[6] Holly Janes,et al. Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.
[7] Jim Schnabel,et al. Neuroscience: Standard model , 2008, Nature.
[8] Christopher F. Martin,et al. Assessment of Serum Proteomics to Detect Large Colon Adenomas , 2008, Cancer Epidemiology, Biomarkers and Prevention.
[9] L. Liotta,et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. , 2008, Clinical chemistry.
[10] D. Ward,et al. Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.
[11] G. Guyatt. Users' guides to the medical literature : essentials of evidence-based clinical practice , 2008 .
[12] D. Chan,et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.
[13] D. Chan,et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.
[14] David F Ransohoff,et al. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. , 2007, Journal of clinical epidemiology.
[15] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[16] Allen F. Shaughnessy,et al. Clinical Epidemiology: A Basic Science for Clinical Medicine , 2007, BMJ : British Medical Journal.
[17] Lennart Martens,et al. The minimum information about a proteomics experiment (MIAPE) , 2007, Nature Biotechnology.
[18] A. Dupuy,et al. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.
[19] S. Markowitz,et al. Improved fecal DNA test for colorectal cancer screening. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] B. H. Patterson,et al. Evaluating markers for the early detection of cancer: overview of study designs and methods , 2006, Clinical trials.
[21] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[22] J. Potter. Epidemiology informing clinical practice: from bills of mortality to population laboratories , 2005, Nature Clinical Practice Oncology.
[23] K. Hede. $104 million proteomics initiative gets green light. , 2005, Journal of the National Cancer Institute.
[24] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[25] P. Qiu. The Statistical Evaluation of Medical Tests for Classification and Prediction , 2005 .
[26] V. Berger. Selection Bias and Covariate Imbalances in Randomized Clinical Trials: Berger/Selection Bias and Covariate Imbalances in Randomized Clinical Trials , 2005 .
[27] J. Ioannidis. Microarrays and molecular research: noise discovery? , 2005, The Lancet.
[28] D. Ransohoff. Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.
[29] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[30] D. Ransohoff,et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.
[31] S. Woolf. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. , 2004, The New England journal of medicine.
[32] E. Diamandis. Proteomic patterns to identify ovarian cancer: 3 years on , 2004, Expert review of molecular diagnostics.
[33] D. Ransohoff. Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.
[34] Jeffrey S. Morris,et al. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..
[35] J. Ioannidis,et al. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment , 2003, The Lancet.
[36] J. Knottnerus,et al. Assessment of the accuracy of diagnostic tests: the cross-sectional study. , 2003, Journal of clinical epidemiology.
[37] D. Ahlquist,et al. DNA integrity as a potential marker for stool-based detection of colorectal cancer. , 2003, Clinical chemistry.
[38] John P A Ioannidis,et al. Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.
[39] D. Ransohoff. Developing Molecular Biomarkers for Cancer , 2003, Science.
[40] David Moher,et al. The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration , 2003, Annals of Internal Medicine [serial online].
[41] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[42] Sudhir Srivastava,et al. Markers for early detection of cancer: Statistical guidelines for nested case-control studies , 2002, BMC medical research methodology.
[43] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[44] Jason E. Stewart,et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.
[45] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[46] S. Thibodeau,et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. , 2000, Gastroenterology.
[47] G. Taubes. Epidemiology faces its limits. , 1995, Science.
[48] S. Cummings,et al. Designing Clinical Research: An Epidemiologic Approach , 1988 .
[49] J. Buring,et al. Epidemiology in Medicine , 1987 .
[50] B. Casto,et al. Conditions for transformation of human fibroblast cells: an overview. , 1986, Cancer letters.
[51] Stephen B. Gruber,et al. Clinical Epidemiology: The Architecture of Clinical Research , 1986, The Yale Journal of Biology and Medicine.
[52] D. Sackett,et al. The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.
[53] R. Fletcher,et al. Clinical Epidemiology: The Essentials , 1982 .